# DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

> **NCT04920617** · PHASE2 · RECRUITING · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 102 (estimated)

## Conditions studied

- Relapsed Diffuse Large B-cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** DPX-Survivac
- **DRUG:** Pembrolizumab
- **DRUG:** CPA

## Key facts

- **NCT ID:** NCT04920617
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-18
- **Primary completion:** 2024-10
- **Final completion:** 2025-04
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2023-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920617, "DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04920617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*